Date: 2015-06-17
Type of information: Financing round
Company: Amicus Therapeutics (USA - NJ)
Investors:
Amount: $258.8 million
Funding type: financing round
Planned used: Amicus Therapeutics expects to use the net proceeds of the offering for investment in the global commercialization infrastructure for Galafold™ (migalastat) for Fabry disease, the continued clinical development of its product candidates and for other general corporate purposes.
Others: * On June 17, 2015, Amicus Therapeutics, a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, announced the closing of its previously announced public offering of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an additional 2,547,170 shares of common stock. As a result, the Company issued a total of 19,528,302 shares in the offering at a price of $13.25 per share. The gross proceeds from the offering to Amicus are expected to be $258.8 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. * On June 11, 2015, Amicus Therapeutics announced the pricing of an underwritten offering of 16,981,132 shares of its common stock at $13.25 per share. The gross proceeds from the offering to Amicus are expected to be $225 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. In addition, Amicus has granted the underwriters a 30-day option to purchase up to an additional 2,547,170 shares of its common stock. The offering is expected to close on June 17, 2015, subject to customary closing conditions. J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Cowen and Company, LLC is acting as lead manager and Janney Montgomery Scott LLC is acting as co-manager for the offering.
Therapeutic area: Rare diseases - Genetic diseases
